Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company’s recent issuance of a U.S. patent covering a variant of ...

FMC63, an IgG2a mouse monoclonal antibody, targets CD19. To date, a majority of the reported CART19 trials include the anti-CD19 scFv extracted from FMC63, such as both the FDA-approved CARs ...

CARGO Therapeutics (CRGX) announced that its first abstract on CRG-023 will be presented as a poster at the upcoming 66th American Society of ...

【导读】为了解决免疫逃逸问题，多特异性CAR-T细胞策略使用能够特异性结合恶性细胞上多个受体的天然配体。在这种情况下，团队提出了一种分体CAR设计，包括在T细胞上表达的通用受体和基于配体的开关分子，这种设计保留了像APRIL和BAFF这样的配体的天然 ...

Here, we have developed a method to insert LT-scFv into the membranes of prokaryotic and eukaryotic cells rapidly and efficiently (Fig. 1). Purified LT-scFvs are brought into contact with cells ...

In a long-term collaboration, we have created a novel method of converting nonneutralizing anti-HIV-1 envelope single chain Fv (scFv) antibody fragments into neutralizing scFvs by targeting expression ...

The production capabilities encompass a broad spectrum of antibody formats, including full-length, scFv, Fab, sdAb/VHH, Fc fusion proteins, chimeric antibodies, and bispecific antibodies.

然而CAR T疗法针对胶质母细胞瘤（Glioblastoma，GBM）在内的诸多实体瘤效果却十分有限。为了进一步提升CAR T细胞在治疗实体瘤时的疗效，当前大多数研究致力于改良CAR ...

证券之星消息，2024年11月4日百普赛斯（301080）发布公告称公司于2024年10月30日接受机构调研，华夏基金、南方基金、长城基金、广发基金、东吴证券、兴业证券、招商证券、其他89家机构参与。